Get the latest tech news
Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.
Eli Lilly’s daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic, according to new data from a Phase 3 trial. Eli Lilly is the maker of the blockbuster GLP-1 drug tirzepatide, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea. “With orforglipron offering additional advantages such as the elimination of strict pre-dosing requirements, potential lower cost, and easier storage, it will be important to see whether these features lead to even greater adherence,” says Priya Jaisinghani, a diabetes and obesity medicine specialist at NYU Langone.
Or read this on Wired